December 2020 edition of Australian Prescriber out now

Limited role of medicines in the treatment of autism

The number of children with autism spectrum disorder is growing, partly due to the way the condition is diagnosed. In an article in Australian Prescriber, Dr Melanie Turner, Child and adolescent psychiatrist and Director of MyChild Psychiatry and Psychology in South Australia, looks at some of the treatment strategies that might be help to manage some of the additional conditions that people with autism often have.

Testing for COVID-19

Diagnostic testing for COVID-19 is a key element in the strategy for limiting its spread. Infectious diseases physicians Drs Anna Brischetto and Jenny Robson explain what the different tests are, when they should be used, what samples should be collected and how to interpret test results.

HIV diagnoses fall as Australians embrace pre-exposure prophylaxis but challenges remain

HIV prevention in Australia has been revolutionised in the past few years by pre-exposure prophylaxis (PrEP) with antiretroviral medicines. Senior researcher and Sexual health physician Dr Nicholas Medland and Program head Professor Andrew Grulich at the University of New South Wales’ Kirby Institute say that Australia is a global leader in the roll-out of PrEP to gay and bisexual men and this should help eliminate HIV transmission.

Management of post-surgical pain in the community

Professor Ross MacPherson and Dr Gavin Pattulo from the Department of Anaesthesia and Pain Management at Sydney’s Royal North Shore Hospital talk about the importance of a post-surgery pain management plan and what should be included. Discussing the plan and setting realistic patient expectations around pain management are important before a patient is discharged.

New label advice for antibiotics

The label attached by pharmacists to antibiotic packaging has previously advised patients to continue taking the antibiotics until they are all finished, which may have contributed to the excessive use of antibiotics and antibiotic resistance. New labelling will now state, ‘Take for the number of days advised by your prescriber.’ This latest news article in Australian Prescriber covers the implications for this for prescribers and pharmacists.

Top 10 drugs of 2019-20

This edition of Australian Prescriber publishes the top 10 drugs prescribed in Australia in 2019–20 under the Pharmaceutical Benefits Scheme (PBS) and Repatriation Pharmaceutical Benefits Scheme (RPBS).

Also in the December issue of Australian Prescriber:

Treatment of vulvovaginitis

Updated Australian guidelines for mild asthma: what’s changed and why?

Medicines Australia Code of Conduct: breaches 2019–20

New drugs: Dinutuximab beta for neuroblastoma, entrectinib for non-small cell lung cancer and solid tumours, lorlatinib for non-small cell lung cancer, and polatuzumab vedotin for B-cell lymphoma.


    Media contact

    Matthew Harris, NPS MedicineWise Communications & PR adviser: (02) 8217 9229, 0419 618 365 or [email protected]